

# AgroGeneration (+)

## H1 Results and company contact

Opinion	<b>BUY</b>
Target price	<b>€ 0,74</b>
Potential	+61%

in € / share	2014	2015e	2016e	2017e
diluted EPS	-0,24	-0,02	0,09	0,16
Chg 1 year	n.s.	n.s.	n.s.	+70,2%
Revisions	n.s.	n.s.	-8,1%	+20,2%

ISIN	FR0010641449
Ticker	ALAGR:FPAA
DJ sector	Food Products Industry

Price	€0,46
Nb of shares (m)	98,5
diluted nb of shares (m)	212,1
Market cap (m€)	45
Float (m€)	9

	1m	3m	1 year
Absolute chg	-8,0%	-23,3%	-6,1%
Relative chg	-19,2%	-17,6%	-18,7%



dec-31	2014	2015e	2016e	2017e
PE	n.s.	n.s.	4,9x	2,9x
EV/CA	1,9x	2,1x	1,6x	1,1x
EV/EBITDA	6,0x	6,8x	4,2x	2,5x
EV/EBITA	9,4x	10,4x	5,2x	2,9x
FCF yield	0,2x	0,4x	0,5x	0,8x
Yield	0,0x	0,0x	0,0x	0,0x
Net debt/EBITDA	3,8x	2,0x	1,1x	0,4x

Claire Barbaret  
+33 (0) 1 44 88 77 93  
cbarbaret@invest-securities.com


## ReGeneration confirmed

**Despite particularly unfavourable conditions, AgroGeneration posted very satisfactory H1 2015 results. EBITDA rose 59% to €8.4m, essentially due to the +30% increase in the change in fair value concerning biological assets reflecting strict cost controls, thereby suggesting substantial leverage over coming years when agricultural commodity prices recover. We are maintaining our BUY rating with a target price unchanged at €0.74.**


- AgroGeneration was hit by three unfavourable external factors in H1: continued depressed economic conditions, a further decline in commodity prices and unfavourable weather conditions (drought with a negative impact on corn and rapeseed yields). Ukraine's economic and political situation has improved in H2. The country obtained a \$1.7bn loan from the IMF and its S&P rating was raised from CCC+ to B-. Additionally agricultural commodity prices have probably bottomed out, with the negative impact of El Nino on palm oil production having already boosted oilseed (rapeseed and sunflower) prices.
- Despite this unfavourable context, the H1 results were good. Given the highly seasonal nature of agricultural cycles, the change in fair value of biological assets (fair value of harvests in the ground minus their associated costs) is substantial as of end June before the harvests. It rose 30% to €11.8m in H1, thereby demonstrating the concrete impact of the good cost controls announced by the group. Rather than an objective for yields, the priority has been placed on the yield / cost trade-off and on the optimisation of the use of inputs. This led to a 59% increase in EBITDA to €8.4m. There should be a significant leverage effect on earnings when prices will recover.
- Net earnings continued to be penalised by high financial charges totalling -€11.8m, including -€8.3m linked to the forex impact due to the local currency (hryvnia) fall. A significant part of these exchange rate losses did not impact the company's cash position. We believe that the hryvnia should stabilise as a result of the start of an economic recovery. Exchange rate effects should be more limited in H2.
- AgroGeneration's financial position improved significantly following the OSRANE (subordinated debt reimbursable in shares) issue at the beginning of the year. Additionally and as expected, asset valuations were revised upward by €25m. Equity funds totalled €59.8m as of end June vs. €6.9m at the end of December 2014. Gearing fell from 1,147% at yearend 2014 to 77% as of end June. The company obtained a \$35m crop loan for the 2015/2016 season from Alfa Bank. Cash generation improved thanks to good control over the change in the WCR, which went from -€7.6m in H1 2014 to €0.9m in H1 2015.
- Despite the downward revision in 2015 revenues to €59.8m vs. the previous €64.4m, we anticipate a more limited drop in EBITDA to €18.5m vs. €20.9m. The EBITDA margin is expected to fall from 32.9% to 31%. We anticipate a virtually equivalent loss of -€8.9m versus -€9.1m due to lower exchange rate losses of -€12.5m vs. -€17.5m. We are maintaining our DCF-based target price of €0.74/share. The improvement in the medium-term outlook thanks to higher operating leverage (positive impact of better cost controls when agricultural prices will recover) has been offset by an increase in the WACC from 19.75% to 22.85% (higher risk-free rate). BUY rating maintained.

## Financial Data

Shareholders	
SBF IV	62%
GreenAlliance	7%
Gravitation	4%
Aloe Private Equity	6%
Free Float	21%




Répartition des récoltes 2014	
Wheat	0,0%
Sunflower	8,1%
Barley	6,3%
Peas	31%
Others	54,6%



2013

28/10/15									
Data per share	2011	2012	2013	2014	2015e	2016e	2017e	2018e	2019e
published EPS	n.a.	n.a.	-0,05	-0,24	-0,09	0,15	0,29	0,42	0,46
<b>diluted EPS</b>	n.a.	n.a.	-0,05	-0,24	-0,02	0,09	0,16	0,22	0,24
<i>Var/consensus</i>	n.a.	n.a.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.
Net asset	n.a.	n.a.	0,79	0,07	0,68	0,83	1,11	1,53	1,99
Dividend	n.a.	n.a.	0,00	0,00	0,00	0,00	0,00	0,00	0,00
Valuation ratios	2011	2012	2013	2014	2015e	2016e	2017e	2018e	2019e
P/E	n.a.	n.a.	n.s.	n.s.	4,9x	2,9x	2,1x	1,9x	
VE/Revenue	n.a.	n.a.	3,6x	1,9x	2,1x	1,6x	1,1x	0,7x	0,3x
VE/EBITDA	n.a.	n.a.	n.s.	6,0x	6,8x	4,2x	2,5x	1,5x	0,7x
VE/EBITA adjusted	n.a.	n.a.	n.s.	9,4x	10,4x	5,2x	2,9x	1,7x	0,8x
op. before BFR FCF yield	n.a.	n.a.	n.s.	0,2x	0,4x	0,5x	0,8x	1,2x	1,3x
operational FCF yield	n.a.	n.a.	0,0x	0,3x	0,5x	0,4x	0,7x	1,0x	1,2x
Yield	n.a.	n.a.	0,0%	0,0%	0,0%	0,0%	0,0%	0,0%	0,0%
EV (€m)	2011	2012	2013	2014	2015e	2016e	2017e	2018e	2019e
Share price in €	n.a.	n.a.	1,5	0,9	0,5	0,5	0,5	0,5	0,5
Capitalization	n.a.	n.a.	123,3	46,0	42,4	42,4	42,4	42,4	42,4
Net debt (OSRANE incl.)	n.a.	n.a.	71,6	77,2	83,1	74,7	60,4	39,5	0,7
Minorities	n.a.	n.a.	0,0	0,0	0,0	0,0	0,0	0,0	0,0
Provisions	n.a.	n.a.	0,7	0,0	0,0	0,0	0,0	0,0	0,0
Others	n.a.	n.a.	0,0	0,0	0,0	0,0	0,0	0,0	0,0
<b>EV</b>	n.a.	n.a.	<b>195,5</b>	<b>123,2</b>	<b>125,5</b>	<b>117,0</b>	<b>102,7</b>	<b>81,8</b>	<b>43,0</b>
P&L (€m)	2011	2012	2013	2014	2015e	2016e	2017e	2018e	2019e
Revenue	n.a.	32,8	53,7	64,6	59,8	73,6	93,7	114,5	126,3
<i>chg.</i>	n.a.	n.s.	63,7%	20,3%	-7,5%	23,1%	27,3%	22,2%	10,3%
EBITDA	n.a.	8,6	-9,8	20,4	18,5	27,6	41,9	56,1	61,2
<b>EBITA adjusted</b>	n.a.	<b>-1,4</b>	<b>-16,8</b>	<b>13,1</b>	<b>12,1</b>	<b>22,4</b>	<b>35,8</b>	<b>48,3</b>	<b>52,8</b>
<i>chg.</i>	n.a.	n.s.	n.s.	n.s.	-8%	+85%	+60%	+35%	+9%
EBIT	n.a.	-1,4	-16,8	13,1	12,1	22,4	35,8	48,3	52,8
Financial result	n.a.	-0,4	-3,5	-36,2	-20,8	-7,7	-7,5	-7,3	-7,3
Taxes	n.a.	-0,3	-0,2	0,0	-0,3	0,0	0,0	0,0	0,0
Minorities	n.a.	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0
Net profit	n.a.	-2,2	-20,5	-23,1	-8,9	14,7	28,4	41,1	45,6
<b>Net profit corrected</b>	n.a.	<b>-2,2</b>	<b>-20,5</b>	<b>-23,1</b>	<b>-8,9</b>	<b>14,7</b>	<b>28,4</b>	<b>41,1</b>	<b>45,6</b>
<i>chg.</i>	n.a.	n.s.	n.s.	n.s.	n.s.	+93%	+45%	+11%	
Cash flow statement (€m)	2011	2012	2013	2014	2015e	2016e	2017e	2018e	2019e
Net profit	n.a.	4,9	-22,6	-23,1	-8,9	14,7	28,4	41,1	45,6
Depreciations & amortizations	n.a.	-3,7	-9,2	-7,3	-6,4	-5,2	-6,1	-7,8	-8,4
Other non cash items	n.a.	-5,7	2,6	27,0	17,5	0,0	0,0	0,0	0,0
<b>op. before BFR FCF</b>	n.a.	<b>2,9</b>	<b>-10,8</b>	<b>11,2</b>	<b>15,0</b>	<b>19,9</b>	<b>34,5</b>	<b>48,9</b>	<b>54,0</b>
Change in WCR	n.a.	-4,5	13,5	0,9	4,6	-3,2	-4,6	-4,8	-2,7
<b>operational FCF</b>	n.a.	<b>-1,6</b>	<b>2,7</b>	<b>12,1</b>	<b>19,6</b>	<b>16,7</b>	<b>29,8</b>	<b>44,0</b>	<b>51,3</b>
Acquisitions/cessions	n.a.	-0,4	-4,3	-3,0	-3,9	-9,5	-11,0	-13,0	-5,5
Capital increase	n.a.	5,0	0,1	0,1	42,3	0,0	0,0	0,0	0,0
Dividends	n.a.	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0
Others	n.a.	-0,5	-0,8	-11,0	-50,1	-0,6	-0,6	-0,6	-0,6
<b>published FCF</b>	n.a.	<b>2,6</b>	<b>-2,3</b>	<b>-1,8</b>	<b>7,8</b>	<b>6,7</b>	<b>18,3</b>	<b>30,5</b>	<b>45,2</b>
Balance sheet (€m)	2011	2012	2013	2014	2015e	2016e	2017e	2018e	2019e
Current assets	n.a.	27,5	94,3	63,6	87,8	92,1	97,0	102,2	99,3
WCR	n.a.	21,7	45,0	22,2	46,0	49,8	54,7	59,9	57,0
Equity group share	n.a.	26,8	28,4	20,2	15,6	18,8	23,5	28,3	31,0
Minorities	n.a.	55,1	51,1	6,6	66,7	81,4	109,8	150,9	196,5
Provisions	n.a.	0,2	0,0	0,0	0,0	0,0	0,0	0,0	0,0
<b>Net debt</b>	n.a.	<b>-1,0</b>	<b>71,6</b>	<b>77,2</b>	<b>37,8</b>	<b>29,4</b>	<b>15,1</b>	<b>-5,8</b>	<b>-44,6</b>
Financial ratios (%)	2011	2012	2013	2014	2015e	2016e	2017e	2018e	2019e
EBITDA/Revenue	n.a.	26,3%	n.s.	31,6%	31,0%	37,5%	44,7%	49,0%	48,5%
EBITA/Revenue	n.a.	n.s.	n.s.	20,3%	20,2%	30,4%	38,2%	42,2%	41,8%
NR corrected/Revenue	n.a.	n.s.	n.s.	n.s.	n.s.	20,0%	30,3%	35,9%	36,1%
WCR /Revenue	n.a.	81,8%	53,0%	31,3%	26,1%	25,6%	25,1%	24,7%	24,6%
ROCE excl. Incorp/ GW	n.a.	-4,3%	-21,6%	21,3%	21,1%	36,6%	54,5%	68,5%	72,1%
ROE corrected	n.a.	n.s.	n.s.	n.s.	n.s.	18,1%	25,8%	27,2%	23,2%
Net debt/Total equity	n.a.	-1,8%	140,2%	1175,0%	56,7%	36,1%	13,7%	-3,9%	-22,7%
Net debt/EBITDA (en x)	n.a;	-0,1x	n.s.	3,8x	2,0x	1,1x	0,4x	-0,1x	-0,7x

## Price change on 5 years (absolute and relative)



## CONFLICT SCREEN

	Corporate Finance	Treasury stocks holding	Prior communication	Analyst's personal interest	Liquidity contract	Listing Sponsor	Research contract
AgroGeneration	Yes	No	Yes	No	No	No	Yes

## DISCLAIMER

This document does not constitute an offer to buy or sell securities issued by the above mentioned company. The foregoing information, forecasts and opinions, are the result of the best efforts of those involved in their compilation, and are believed to be coherent and reasonable. The directors, managers and employees of Invest Securities cannot be held responsible for the accuracy and completeness of this document's contents as a consequence of any form of guarantee. No individual can be held liable for any loss resulting from the use of this document, or any element thereof, to invest in marketable securities. The conditions for the preparation, production and distribution of this research are fully compliant with articles 321-122 to 321-142 of the "AMF"- the French financial markets regulator.

The information contained in this document has been derived from sources deemed to be reliable. However, we will not accept any liability in case of error or omission.

Invest Securities, 73 boulevard Haussmann 75008 PARIS, France

Tel : + 33 (0) 1 44 88 77 88

**Financial Analysis****Daniel Anizon, Biotechs / Medtechs**

+33 1 44 88 77 88

danizon@invest-securities.com

**Claire Barbaret, Stock-Picking**

+33 1 44 88 77 88

cbarbaret@invest-securities.com

**Martial Descoutures, Santé / Biotechs**

+33 1 44 88 88 09

mdescoutures@invest-securities.com

**Maxime Dubreil, Editeurs Logiciels / Technos**

+33 1 44 88 77 98

mdubreil@invest-securities.com

**Benoit Faure-Jarrosson, Immobilier**

+33 1 44 88 77 88

bfaure-jarrosson@invest-securities.com

**Peter Farren, Biens de Consommation**

+33 1 73 73 90 36

pfarren@invest-securities.com

**Farid Kassa, Immobilier**

+33 1 73 73 90 27

fkassa@invest-securities.com

**Vladimir Minot, Immobilier**

+33 1 73 73 90 25

vminot@invest-securities.com

**Jean-Louis Sempé, Automobile / Sidérurgie**

+33 1 73 73 90 35

jlsempe@invest-securities.com

**Thibaut Voglimacci-Stephanopoli, Medtechs / Biotechs**

+33 1 44 88 77 95

tvoglimacci@invest-securities.com

**Laurent Wilk, Cleantech**

+33 1 44 88 77 97

lwilk@invest-securities.com

**Traders****Eric d'Aillières**

+33 1 55 35 55 62

edaillieres@invest-securities.com

**Claude Bouyer**

+33 1 44 88 88 02

clbouyer@invest-securities.com

**Jean Philippe Coulon**

+33 1 55 35 55 64

jpcoulon@invest-securities.com

**François Habrias**

+33 1 55 35 55 70

fhabrias@invest-securities.com

**Pascal Hadjedj**

+33 1 55 35 55 61

phadjedj@invest-securities.com

**Dominique Humbert**

+33 1 55 35 55 64

dhumbert@invest-securities.com

**Bertrand Le Mollé-Montanguon**

+33 1 55 35 55 74

blmm@invest-securities.com

**Nicolas Michaux**

+33 1 55 35 55 73

nmichaux@invest-securities.com

**Sylvain Navarro**

+33 1 55 35 55 69

snavarro@invest-securities.com

**Ralph Olmos**

+33 1 55 35 55 72

rolmos@invest-securities.com

**René Reymond**

+33 1 55 35 55 63

rreymond@invest-securities.com

**Thierry Roussilhe**

+33 1 55 35 55 66

troussilhe@invest-securities.com

**Kaspar Stuart**

+33 1 55 35 55 65

kstuart@invest-securities.com

**Renaud Vallette Viallard**

+33 6 29 48 42 32

rvv@invest-securities.com

**Frédéric Vals**

+33 1 55 35 55 71

fvals@invest-securities.com